SLC28A2

Sodium/nucleoside cotransporter 2 · O43868 · SLC28A2 on Sugi Atlas →

21,573 patent compounds predicted against SLC28A2, 16,697 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL578218	0.66	3/20
SCHEMBL472569	0.58	3/20
SCHEMBL472571	0.58	3/20
Inosine (SCHEMBL222073)	0.67	2/20
Adenosine (SCHEMBL192733)	0.63	2/20
SCHEMBL440925	0.62	2/20
SCHEMBL440926	0.62	2/20
Adenosine (SCHEMBL438282)	0.55	2/20
SCHEMBL42103	0.50	2/20
SCHEMBL288517	0.50	2/20
SCHEMBL622587	0.47	2/20
SCHEMBL646291	0.47	2/20
Adenosine (SCHEMBL731)	1.00	1/20
Phlorizin (SCHEMBL17290)	1.00	1/20
Uridine (SCHEMBL20667)	1.00	1/20
Adenosine (SCHEMBL63363)	1.00	1/20
Vidarabine (SCHEMBL110914)	1.00	1/20
Phlorizin (SCHEMBL113699)	1.00	1/20
Adenosine (SCHEMBL134719)	1.00	1/20
Adenosine (SCHEMBL170902)	1.00	1/20

Clinical trials — most relevant to SLC28A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Ticagrelor in Remote Ischemic Preconditioning Study	PHASE4	COMPLETED
Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure	PHASE4	RECRUITING
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Genetic Basis for Variation in the Renal Elimination of Metformin	PHASE4	COMPLETED
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.	PHASE4	COMPLETED
COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure	PHASE4	COMPLETED
Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)	PHASE4	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD	PHASE3	COMPLETED
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE3	COMPLETED
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin	PHASE2	NOT_YET_RECRUITING
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes	PHASE2	COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I	EARLY_PHASE1	COMPLETED
Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin	nan	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Renal Transporters After Renal Transplantation	nan	UNKNOWN
ISGLT2 in Patients Without DM With Acute MI	nan	COMPLETED
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.	nan	RECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients	nan	UNKNOWN
Dapagliflozin in the Treatment of Heart Failure	nan	UNKNOWN
Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure	nan	COMPLETED
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients	nan	COMPLETED
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction	nan	COMPLETED
Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment	nan	COMPLETED
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLC28A2 binder may also engage these)

Protein	Name	Similarity
O88627	—	1.000	O88627 →
Q62773	—	1.000	Q62773 →
Q9MZT2	—	1.000	Q9MZT2 →
E9PXX9	—	0.998	E9PXX9 →
Q62674	—	0.998	Q62674 →
SLC28A1	Sodium/nucleoside cotransporter 1	0.998	landscape →
Q8VIH3	—	0.996	Q8VIH3 →
SLC28A3	Solute carrier family 28 member 3	0.995	landscape →
Q9ERH8	—	0.993	Q9ERH8 →
Q9UA35	—	0.992	Q9UA35 →
O62667	—	0.992	O62667 →
P51905	—	0.987	P51905 →
Q8VBW1	—	0.986	Q8VBW1 →
B4JMC1	—	0.986	B4JMC1 →
O88575	—	0.984	O88575 →
B0JZG0	—	0.984	B0JZG0 →
Q9MYX0	—	0.984	Q9MYX0 →
Q9MZ34	—	0.984	Q9MZ34 →
P48029	—	0.984	P48029 →
SLC6A4	Sodium-dependent serotonin transporter	0.984	landscape →
O18875	—	0.983	O18875 →
Q00589	—	0.983	Q00589 →
A7Y2X0	—	0.983	A7Y2X0 →
P31652	—	0.983	P31652 →
P23977	—	0.983	P23977 →
Q61327	—	0.982	Q61327 →
Q29GB8	—	0.982	Q29GB8 →
Q9GJT6	—	0.982	Q9GJT6 →
P31661	—	0.982	P31661 →
Q69RI8	—	0.982	Q69RI8 →